|
0
|
|
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
(linkinghub.elsevier.com)
|
Giovannoni G
…
Oh J
The Lancet
2026-05-30
|
#clinical trial
#immunotherapy
#multiple sclerosis
#disability progression
|
|
0
|
|
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
(linkinghub.elsevier.com)
|
Nikolcheva T
…
Bonni A
The Lancet
2026-05-30
|
#clinical trial
#immunotherapy
#neurodegeneration
#neuroprotection
|
|
0
|
|
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
(nejm.org)
|
Agarwal N
…
Fizazi K
New England Journal of Medicine
2026-05-30
|
#cancer
#clinical trial
#therapeutics
#dna repair
#prostate
|
|
0
|
|
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
(linkinghub.elsevier.com)
|
Hauser SL
…
Kappos L
The Lancet
2026-05-30
|
#antibody
#clinical trial
#immunotherapy
#multiple sclerosis
|
|
0
|
|
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
(linkinghub.elsevier.com)
|
Cummings JL
…
Feldman HH
The Lancet
2026-05-30
|
#clinical trial
#neurodegeneration
#neuroprotection
#pharmacotherapy
#dementia
|